ZoomMed Inc. has signed an exclusive license agreement regarding the rights to distribute, license and sub-license the ZRx Prescriber in the United States for a consideration of more than $3.5 million, with EvEMR Inc. In consideration of the grant of the license, EvEMR will pay to ZoomMed a cash amount of $1.5 million, will issue to ZoomMed 2 million Preferred shares and 2 million participating, non-voting shares in the capital stock of EvEMR representing an additional 10% of the total economic interest in EvEMR, which economic interest value has not yet been determined.